Comparing Cefepime Versus Cefazolin Plus Ceftazidime for CAPD-associated Peritonitis

Sponsor
Chulalongkorn University (Other)
Overall Status
Completed
CT.gov ID
NCT02872038
Collaborator
The Kidney Foundation of Thailand (Other), Siam Pharmaceutical Co Ltd (Other)
154
1
2
16
9.6

Study Details

Study Description

Brief Summary

The purpose of this study is to compare the efficacy of empirical antibiotics of CAPD-associated peritonitis with intraperitoneal, continuous dosing of cefepime monotherapy versus combination of cefazolin and ceftazidime. Patients were randomized to be administered either intraperitoneal cefepime 1 g loading then 250 mg all exchanges (treatment group) or cefazolin and ceftazidime (control group) in the same dose.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

The International Society of Peritoneal Dialysis (ISPD) guideline suggest to use combination of antibiotics to cover both of gram positive and gram negative bacteria. The usual regimen in Thailand is cefazolin plus ceftazidime. Despite combination therapy, monotherapy is also possible for empirical treatment of CAPD-associated peritonitis since it helps to lowering staff burden and lowering risk of contamination. Cefepime could be an ideal antibiotic for empirical treatment of CAPD-associated peritonitis as it is an extended-spectrum cephalosporin, forth generation, covering most of gram positive and gram negative bacteria. In addition, cefepime is not broken down by many of the beta-lactamases and less beta-lactamases inducer. This study aims to prove the noninferiority of cefepime monotherapy to cefazolin plus ceftazidime for empirical treatment of CAPD-associated peritonitis.

CAPD-associated peritonitis was diagnosed by at least two of the following criteria:

abdominal pain or cloudy peritoneal dialysis fluid (PDF); PDF white cell count > 100/μL with

50% polymorphonuclear(PMN); and positive gram stain or culture. The patients were randomized into two groups by block of four randomization, sealed envelope. Treatment group was treated with intraperitoneal (IP) cefepime 1 g loading following by maintenance dose 250 mg IP all exchanges. Control group was treated with cefazolin 1 g IP loading and ceftazidime 1 g IP loading following by maintenance dose of cefazolin and ceftazidime 250 mg IP all exchanges. If a patient had residual urine ≥ 100 ml/day, dose of antibiotics would be increased by 25%.

On the first day, the initial blood tests for complete blood count, electrolyte, BUN, creatinine, calcium, phosphate and magnesium were obtained. While peritoneal dialysis fluid were collected using two methods of bacterial culture, both of centrifugation of 50 ml peritoneal dialysis fluid at 3,000 g for 15 minutes and bedside 5-10 ml of peritoneal dialysis fluid inoculated into the blood culture bottles. PDF gram stain and bacterial culture were done. The patients were followed on day 3, 5, 10, 14, 21 and 28 days after the completion of antibiotic course. If clinical improved, the antibiotics would be adjusted according to the culture result and sensitivity after day 5. If clinical not improved the antibiotics would be step up and Tenckhoff catheter removal was considered (on any day of treatment). The patients were treated at least 14 days or 21 days depend on the culture result (as the recommendation of ISPD guideline 2010).

Study Design

Study Type:
Interventional
Actual Enrollment :
154 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Multicenter, Randomized, Controlled Trial Comparing Cefepime Monotherapy Versus Combination of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-associated Peritonitis
Study Start Date :
Aug 1, 2015
Actual Primary Completion Date :
Nov 30, 2016
Actual Study Completion Date :
Nov 30, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment

Cefepime intraperitoneal continuous dosing

Drug: Cefepime
Cefepime intraperitoneal continuous dosing

Active Comparator: Control

Cefazolin plus Ceftazidime intraperitoneal continuous dosing

Drug: Cefazolin plus Ceftazidime
Other Names:
  • Control group
  • Outcome Measures

    Primary Outcome Measures

    1. Primary response rate [day 10 of treatment]

      Resolution of clinical peritonitis and peritoneal dialysis fluid WBC < 100 /μL with PMN < 50% at day 10

    Secondary Outcome Measures

    1. Initial response rate [day 5 of treatment]

      Resolution of clinical peritonitis and peritoneal dialysis fluid WBC < 100 /μL with PMN < 50% at day 5

    Other Outcome Measures

    1. Complete cure rate [28 days after completion of antibiotics]

      Complete resolution without relapse or recurrent within 28 days after completion of antibiotics.

    2. Relapse peritonitis rate [28 days after completion antibiotics]

      Recur of peritonitis with the same organism or sterile culture within 28 days after completion antibiotics

    3. Recurrent peritonitis rate [28 days after completion antibiotics]

      Recur of peritonitis with different organism within 28 days after completion antibiotics

    4. Death rate [28 days after completion antibiotics]

      Death from any cause

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age more than 18 years

    • CAPD initiation more than 4 weeks

    Exclusion Criteria:
    • Exit site or tunnel infection

    • Sepsis

    • Previous CAPD-associated peritonitis treatment within 4 weeks

    • Drug allergy to cephalosporin

    • Tenckhoff catheter malfunction

    • Hospitalization more than 48 hours

    • Fungal or Mycobacterium infection

    • Suspected secondary peritonitis

    • Concomitant antibiotics.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Chulalongkorn University Bangkok Thailand 10500

    Sponsors and Collaborators

    • Chulalongkorn University
    • The Kidney Foundation of Thailand
    • Siam Pharmaceutical Co Ltd

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Thidarat Kitrungphaiboon, MD, Fellow of Nephrology, Chulalongkorn University
    ClinicalTrials.gov Identifier:
    NCT02872038
    Other Study ID Numbers:
    • MONOCEF
    First Posted:
    Aug 18, 2016
    Last Update Posted:
    Oct 31, 2017
    Last Verified:
    Oct 1, 2017
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 31, 2017